Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antibody-drug conjugates (ADCs) are the kind of potentially new anti-tumor drugs, consisting of monoclonal antibodies conjugated to the cytotoxic payloads via the synthetic linkers. They have a broad application prospect in solid tumors such as lung cancer. This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC. .
【中文题目：抗体偶联药物在晚期非小细胞肺癌中的 研究进展】 【中文摘要：肺癌是全球发病率和死亡率最高的恶性肿瘤之一，非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌重要的病理类型之一，且晚期患者预后较差，内科治疗仍是其主要治疗手段。抗体偶联药物（antibody-drug conjugates, ADCs）是一类非常有潜力的新型抗肿瘤药物，由单克隆抗体和小分子细胞毒药物通过连接子偶联而成，在肺癌等实体瘤中应用前景广阔。本文对现阶段ADCs在晚期NSCLC中的作用机制和研究进展进行综述。 】 【中文关键词：肺肿瘤；抗体偶联药物；人表皮生长因子受体2】.
Keywords: Antibody-drug conjugates; Human epidermal growth factor receptor 2; Lung neoplasms.